Chronic Granulomatous Disease Research Services
Researchers studying Chronic Granulomatous Disease (CGD) encounter multiple obstacles including the need to elucidate etiologic mechanisms more clearly and to create improved treatment methods. Protheragen provides rare disease research services and supports scientists in advancing their study of CGD through diagnostic and therapeutic development.
What Is Chronic Granulomatous Disease?
Chronic Granulomatous Disease is a rare genetic disorder that affects phagocytic cells so patients cannot eliminate bacterial and fungal infections effectively which leads to frequent serious infections and granulomatous inflammation.
Causes of Chronic Granulomatous Disease
CGD is caused by mutations in the genes for the NADPH oxidase complex, which is responsible for producing superoxide to kill pathogens. The main genes involved include CYBA, CYBB, NCF1, NCF2 and NCF4. Mutations in these genes cause phagocytes to be unable to efficiently produce reactive oxygen species (ROS), thus failing to kill hydrogen peroxide-positive bacteria, such as Staphylococcus aureus, Pneumocystis carinii, and Escherichia coli. In addition, CGD may be associated with abnormal function of multiple cell types (e.g., macrophages, neutrophils, etc.) in the immune microenvironment.
Figure 1. Nicotinamide adenine dinucleotide phosphate (NADPH) oxidase system. (Rider NL, et al., 2018)Therapeutic Strategies for Chronic Granulomatous Disease
- Antibiotic, immunosuppressive therapy
- Hematopoietic stem cell transplantation
Disclaimer: Protheragen specializes in providing preclinical research services. The above is for informational purposes only. For guidance on treatment options, please visit the regular hospital.
Our Services
Biomarker Development for Chronic Granulomatous Disease
Our methods for the detection of immune markers in blood:
- Enzyme-linked immunosorbent assay
- Chemiluminescent immunoassay
- Immunochromatography
- Single-molecule immunoarray technique
- Flow cytometry
- Novel immunoassays based on nanotechnology and artificial intelligence
- Immunoprecipitation-Mass Spectrometry
The low concentration of markers in blood and their susceptibility to other interfering factors can be overcome by our highly sensitive detection technology. We have established uniform operating procedures and quality control standards that can improve the consistency and reliability of test results.
Model Development Services for Chronic Granulomatous Disease
In Vitro Models
- Human induced pluripotent stem cells (iPSCs)
- THP-1 cells with specific genes knocked out or mutated
- Human peripheral blood mononuclear cells (PBMC)
In Vivo Models
- Knockout mouse models
- Zebrafish models
- Humanized mouse models
- Non-human primate models
Are you facing many challenges in your current research? For example, complex host-antigen interactions, poor understanding of granuloma dynamics, and issues of safety and efficacy of therapeutic strategies. We can customize in vitro and in vivo models of CGD to suit your research objectives, and these models can help you better understand the pathogenesis of CGD and develop therapeutic strategies.
Therapy Development Services for Chronic Granulomatous Disease
Types of therapy development we support:
- Small molecule drug development
- Therapeutic antibody development
- Cell therapy development
- Probiotics therapy development
- Gene therapy development
CGD treatment strategies are diverse, ranging from traditional antibiotic and immunomodulatory therapies to emerging gene therapies and hematopoietic stem cell transplantation, and are constantly being optimized. Protheragen is committed to helping researchers make significant advances in the development of therapeutic approaches for CGD.
Reference
- Rider NL, Jameson MB, Creech CB. Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease. J Pediatric Infect Dis Soc. 2018; 7(suppl_1): S2-S5.
All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.